Chitotriosidase As a Biomarker of Cerebral Adrenoleukodystrophy

Overview

Journal J Neuroinflammation

Publisher Biomed Central

Date 2011 Oct 22

PMID 22014002

Citations 20

Authors

Paul J Orchard

Troy Lund

Wes Miller

Steven M Rothman

Gerald Raymond

David Nascene

Lisa Basso

James Cloyd

Jakub Tolar

Affiliations

Soon will be listed here.

Abstract

Background: Adrenoleukodystrophy (ALD) is an X-linked peroxisomal disorder characterized by the abnormal beta-oxidation of very long chain fatty acids (VLCFA). In 35-40% of children with ALD, an acute inflammatory process occurs in the central nervous system (CNS) leading to demyelination that is rapidly progressive, debilitating and ultimately fatal. Allogeneic hematopoietic stem cell transplantation (HSCT) can halt disease progression in cerebral ALD (C-ALD) if performed early. In contrast, for advanced patients the risk of morbidity and mortality is increased with transplantation. To date there is no means of quantitating neuroinflammation in C-ALD, nor is there an accepted measure to determine prognosis for more advanced patients.

Methods: As cellular infiltration has been observed in C-ALD, including activation of monocytes and macrophages, we evaluated the activity of chitotriosidase in the plasma and spinal fluid of boys with active C-ALD. Due to genotypic variations in the chitotriosidase gene, these were also evaluated.

Results: We document elevations in chitotriosidase activity in the plasma of patients with C-ALD (n = 38; median activity 1,576 ng/mL/hr) vs. controls (n = 16, median 765 ng/mL/hr, p = 0.0004), and in the CSF of C-ALD patients (n = 38; median activity 4,330 ng/mL/hr) vs. controls (n = 16, median 0 ng/mL/hr, p < 0.0001). In addition, activity levels of plasma and CSF chitotriosidase prior to transplant correlated with progression as determined by the Moser/Raymond functional score 1 year following transplantation (p = 0.002 and < 0.0001, respectively).

Conclusions: These findings confirm elevation of chitotriosidase activity in patients with active C-ALD, and suggest that these levels predict prognosis of patients with C-ALD undergoing transplantation.

Citing Articles

From gene to therapy: a review of deciphering the role of ABCD1 in combating X-Linked adrenoleukodystrophy.

Zuo X, Chen Z Lipids Health Dis. 2024; 23(1):369.

PMID: 39529100 PMC: 11552335. DOI: 10.1186/s12944-024-02361-0.

Follow-up of pre-motor symptoms of Parkinson's disease in adult patients with Gaucher disease type 1 and analysis of their lysosomal enzyme profiles in the CSF.

Machado Bressan Wilke M, Poswar F, Borelli W, Michelin Tirelli K, Randon D, Lopes F Orphanet J Rare Dis. 2023; 18(1):309.

PMID: 37784132 PMC: 10546662. DOI: 10.1186/s13023-023-02875-3.

Glycoprotein nonmetastatic melanoma protein B (GNMPB) as a novel biomarker for cerebral adrenoleukodystrophy.

Taghizadeh L, King C, Nascene D, Gupta A, Orchard P, Higgins L Sci Rep. 2022; 12(1):7985.

PMID: 35568699 PMC: 9107455. DOI: 10.1038/s41598-022-11552-7.

Evaluation of Neurofilament Light Chain as a Biomarker of Neurodegeneration in X-Linked Childhood Cerebral Adrenoleukodystrophy.

Wang H, Davison M, Kramer M, Qiu W, Gladysheva T, Chiang R Cells. 2022; 11(5).

PMID: 35269535 PMC: 8909395. DOI: 10.3390/cells11050913.

Molecular Biomarkers for Adrenoleukodystrophy: An Unmet Need.

Honey M, Jaspers Y, Engelen M, Kemp S, Huffnagel I Cells. 2021; 10(12).

PMID: 34943935 PMC: 8699919. DOI: 10.3390/cells10123427.

References

Moser H, Raymond G, Dubey P . Adrenoleukodystrophy: new approaches to a neurodegenerative disease. JAMA. 2005; 294(24):3131-4. DOI: 10.1001/jama.294.24.3131. View

Loes D, Stillman A, Hite S, Shapiro E, Lockman L, Latchaw R . Childhood cerebral form of adrenoleukodystrophy: short-term effect of bone marrow transplantation on brain MR observations. AJNR Am J Neuroradiol. 1994; 15(9):1767-71. PMC: 8333734. View

Powers J, Pei Z, Heinzer A, Deering R, Moser A, Moser H . Adreno-leukodystrophy: oxidative stress of mice and men. J Neuropathol Exp Neurol. 2005; 64(12):1067-79. DOI: 10.1097/01.jnen.0000190064.28559.a4. View

Boot R, Renkema G, Verhoek M, Strijland A, Bliek J, de Meulemeester T . The human chitotriosidase gene. Nature of inherited enzyme deficiency. J Biol Chem. 1998; 273(40):25680-5. DOI: 10.1074/jbc.273.40.25680. View

Hollak C, Van Weely S, van Oers M, Aerts J . Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest. 1994; 93(3):1288-92. PMC: 294082. DOI: 10.1172/JCI117084. View

Schoonhoven A, Rudensky B, Elstein D, Zimran A, Hollak C, Groener J . Monitoring of Gaucher patients with a novel chitotriosidase assay. Clin Chim Acta. 2007; 381(2):136-9. DOI: 10.1016/j.cca.2007.02.042. View

Malaguarnera L, Simpore J, Prodi D, Angius A, Sassu A, Persico I . A 24-bp duplication in exon 10 of human chitotriosidase gene from the sub-Saharan to the Mediterranean area: role of parasitic diseases and environmental conditions. Genes Immun. 2003; 4(8):570-4. DOI: 10.1038/sj.gene.6364025. View

Loes D, Fatemi A, Melhem E, Gupte N, Bezman L, Moser H . Analysis of MRI patterns aids prediction of progression in X-linked adrenoleukodystrophy. Neurology. 2003; 61(3):369-74. DOI: 10.1212/01.wnl.0000079050.91337.83. View

Mahmood A, Dubey P, Moser H, Moser A . X-linked adrenoleukodystrophy: therapeutic approaches to distinct phenotypes. Pediatr Transplant. 2005; 9 Suppl 7:55-62. DOI: 10.1111/j.1399-3046.2005.00447.x. View

10.

Sotgiu S, Musumeci S, Marconi S, Gini B, Bonetti B . Different content of chitin-like polysaccharides in multiple sclerosis and Alzheimer's disease brains. J Neuroimmunol. 2008; 197(1):70-3. DOI: 10.1016/j.jneuroim.2008.03.021. View

11.

Aerts J, Hollak C, van Breemen M, Maas M, Groener J, Boot R . Identification and use of biomarkers in Gaucher disease and other lysosomal storage diseases. Acta Paediatr Suppl. 2005; 94(447):43-6. DOI: 10.1111/j.1651-2227.2005.tb02110.x. View

12.

Sotgiu S, Barone R, Arru G, Fois M, Pugliatti M, Sanna A . Intrathecal chitotriosidase and the outcome of multiple sclerosis. Mult Scler. 2006; 12(5):551-7. DOI: 10.1177/1352458506070614. View

13.

Rodrigues M, Sa Miranda M, Amaral O . Allelic frequency determination of the 24-bp chitotriosidase duplication in the Portuguese population by real-time PCR. Blood Cells Mol Dis. 2004; 33(3):362-4. DOI: 10.1016/j.bcmd.2004.07.005. View

14.

Casal J, Lacerda L, Perez L, Pinto R, Clara Sa Miranda M, Tutor J . Relationships between serum markers of monocyte/macrophage activation in type 1 Gaucher's disease. Clin Chem Lab Med. 2002; 40(1):52-5. DOI: 10.1515/CCLM.2002.010. View

15.

Powers J, Liu Y, Moser A, Moser H . The inflammatory myelinopathy of adreno-leukodystrophy: cells, effector molecules, and pathogenetic implications. J Neuropathol Exp Neurol. 1992; 51(6):630-43. DOI: 10.1097/00005072-199211000-00007. View

16.

Loes D, Hite S, Moser H, Stillman A, Shapiro E, Lockman L . Adrenoleukodystrophy: a scoring method for brain MR observations. AJNR Am J Neuroradiol. 1994; 15(9):1761-6. PMC: 8333737. View

17.

Cartier N, Hacein-Bey-Abina S, Bartholomae C, Veres G, Schmidt M, Kutschera I . Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science. 2009; 326(5954):818-23. DOI: 10.1126/science.1171242. View

18.

Verbeek M, Notting E, Faas B, Claessens-Linskens R, Jongen P . Increased cerebrospinal fluid chitotriosidase index in patients with multiple sclerosis. Acta Neurol Scand. 2009; 121(5):309-14. DOI: 10.1111/j.1600-0404.2009.01242.x. View

19.

Kemp S, Pujol A, Waterham H, van Geel B, Boehm C, Raymond G . ABCD1 mutations and the X-linked adrenoleukodystrophy mutation database: role in diagnosis and clinical correlations. Hum Mutat. 2001; 18(6):499-515. DOI: 10.1002/humu.1227. View

20.

Peters C, Charnas L, Tan Y, Ziegler R, Shapiro E, DeFor T . Cerebral X-linked adrenoleukodystrophy: the international hematopoietic cell transplantation experience from 1982 to 1999. Blood. 2004; 104(3):881-8. DOI: 10.1182/blood-2003-10-3402. View